CClinicalTrials.gg
RecruitingNCT03022682IDEOUpdated Sep 8, 2026

Inflammation, Diabetes, Ethnicity and Obesity Cohort

An observational study in Obesity, Diabetes Mellitus and Pre Diabetes, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by University of California, San Francisco · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Obesity affects over one third of US adults (>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associated with increased mortality through its linkage to comorbidities including diabetes, hypertension, dyslipidemia, osteoarthritis, sleep apnea and psychosocial disturbances. Given its prevalence, impact on morbidity and mortality, and economic cost, limiting the spread of obesity and its consequences is one of the most important problems of our time.

In this proposed study, investigators will recruit participants from a wide range of body mass index (BMI), ethnicity and Diabetes risk to collect data and blood, stool and adipose tissue samples in the San Francisco bay area.

Read the detailed description

The Inflammation, Diabetes, Ethnicity and Obesity (IDEO) cohort is recruiting 350 individuals from various ethnicities, covering a spectrum of weight and Diabetes risk. The study is looking for participants between the ages of 18-75 years that are healthy with or without diabetes with a stable weight. The study will also like to include people who are slated to undergo any type of bariatric surgery for obesity or any other type of abdominal surgery at UCSF.

02

Conditions studied

  • Obesity
  • Diabetes Mellitus
  • Pre Diabetes

Keywords

  • ethnicity
  • inflammation
  • obesity
  • diabetes
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

IDEO Cohort participants

Inclusion criteria

  • Participants will be healthy individuals between the ages of 18-75 years. These cutoffs are designed to allow inclusion of postmenopausal women, and younger/more active patients who are increasingly undergoing bariatric surgery.
  • Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort.

Exclusion criteria

Exclusion Criteria:

  • Participants with chronic kidney disease (> stage 4)
  • Autoimmune/inflammatory disease (e.g., Lupus, Ulcerative Colitis, etc.)
  • Unstable angina, New York (NY) class III or IV congestive heart failure or myocardial infarction within 3 months of entry
  • Clinically significant liver disease (e.g. Cirrhosis or liver failure)
  • Weight > 450 pounds (DXA scan weight limit)
  • History of organ transplant
  • Treatment with chemotherapy or radiation therapy at the time of enrollment in study.
  • Poorly controlled asthma (participants requiring inhaled glucocorticoids and/or oral glucocorticoids)
  • Current nasal corticosteroid use (within the past month)
  • Excessive alcohol or substance abuse
  • Current use of anabolic steroids or testosterone for bodybuilding purposes. Testosterone use is permitted if prescribed for hypogonadism and dose stable for the past 6 months.
  • Patients actively enrolled in interventional trials involving investigational agents
  • Pregnant or breast-feeding women
  • Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.
  • History of abnormal clotting
  • Previous bariatric surgery
  • Anticoagulant use
  • Methadone medication
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • IDEO Cohort

    Adipose tissue samples are collected from all participants, including aspirational subcutaneous biopsies from nonsurgical participants and excisional biopsies, performed intra-operatively by surgical collaborators as required. Participants also undergo anthropometric measurements, stool collection, blood sample collection for circulating blood cells, serum, and plasma. Dual-energy x-ray absorptiometry (DXA) scan for amount and distribution of body fat as well as bone density is performed. Study participants complete validated questionnaire inventories to measure bio-behavioral issues such as depression, stress, health locus of control, and dietary habits.

05

What researchers measure

Primary outcomes

  1. Complete recruitment of IDEO cohort participants to spur novel and creative interactions between investigators that have transformative potential in obesity research.

    Number of biological samples collected

    Time frame: 7 years

Secondary outcomes

  1. Adipose tissue inflammation and fibrosis

    Quantification of pro-fibrotic and pro-inflammatory markers in the visceral and subcutaneous adipose tissue

    Time frame: 7 years

06

Study locations

1 of 1 sites recruiting
  • University of California San Francisco
    San Francisco, California 94143, United States
    Recruiting
07

References and documents

Publications

  • Alba DL, Abdellatif A, Choi MK, Brown Mayfield SM, Pham TAT, Berrios DI, Rodriguez AE, Ewing M, Figueroa TR, Gonzalez-Vargas J, Zhang N, An Z, Bu D, Deeks SG, Scherer PE, Hunt PW, Koliwad SK. A distinct form of fat fibrosis is linked to insulin resistance in people with HIV. JCI Insight. 2026 Jun 30;11(15):e195922. doi: 10.1172/jci.insight.195922. eCollection 2026 Aug 10. PubMed 42378059 ↗
  • Koppel N, Bisanz JE, Pandelia ME, Turnbaugh PJ, Balskus EP. Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. Elife. 2018 May 15;7:e33953. doi: 10.7554/eLife.33953. PubMed 29761785 ↗

Related links

08

Registry details

Key details

Study ID
NCT03022682
Lead sponsor
University of California, San Francisco
Responsible party
Sponsor
First posted
Jan 16, 2017
Start date
Feb 2015
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Suneil Koliwad, MD,PhD
principal investigator · University of California, San Francisco
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion